Literature DB >> 27111045

Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect?

B S Andersson1, B C Valdez1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27111045     DOI： 10.1038/bmt.2016.110

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  18 in total

1.  Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.

Authors:  A Shimoni; I Hardan; N Shem-Tov; M Yeshurun; R Yerushalmi; A Avigdor; I Ben-Bassat; A Nagler
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

2.  Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.

Authors:  Christopher G Kanakry; Paul V O'Donnell; Terry Furlong; Marcos J de Lima; Wei Wei; Marta Medeot; Marco Mielcarek; Richard E Champlin; Richard J Jones; Peter F Thall; Borje S Andersson; Leo Luznik
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

Review 3.  Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.

Authors:  Benigno C Valdez; Borje S Andersson
Journal:  Environ Mol Mutagen       Date:  2010-07       Impact factor: 3.216

4.  DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.

Authors:  T Yamauchi; B J Nowak; M J Keating; W Plunkett
Journal:  Clin Cancer Res       Date:  2001-11       Impact factor: 12.531

5.  Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.

Authors:  J De La Serna; J Sanz; A Bermúdez; M Cabrero; D Serrano; C Vallejo; V Gómez; J M Moraleda; S G Perez; M D Caballero; E Conde; J J Lahuerta; G Sanz
Journal:  Bone Marrow Transplant       Date:  2016-03-07       Impact factor: 5.483

6.  Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

Authors:  Borje S Andersson; Marcos de Lima; Peter F Thall; Xuemei Wang; Daniel Couriel; Martin Korbling; Soonja Roberson; Sergio Giralt; Betty Pierre; James A Russell; Elizabeth J Shpall; Roy B Jones; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

7.  Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.

Authors:  Je-Hwan Lee; Young-Don Joo; Hawk Kim; Hun Mo Ryoo; Min Kyoung Kim; Gyeong-Won Lee; Jung-Hee Lee; Won-Sik Lee; Jae-Hoo Park; Sung-Hwa Bae; Myung Soo Hyun; Dae-Young Kim; Sung-Doo Kim; Young Joo Min; Kyoo-Hyung Lee
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

8.  Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?

Authors:  S Chunduri; L C Dobogai; D Peace; Y Saunthararajah; J Quigley; Y-H Chen; N Mahmud; E Hurter; R Beri; D Rondelli
Journal:  Bone Marrow Transplant       Date:  2008-02-11       Impact factor: 5.483

9.  High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.

Authors:  J R Long-Boyle; K G Green; C G Brunstein; Q Cao; J Rogosheske; D J Weisdorf; J S Miller; J E Wagner; P B McGlave; P A Jacobson
Journal:  Bone Marrow Transplant       Date:  2010-04-12       Impact factor: 5.483

10.  Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.

Authors:  Hui Liu; Xiao Zhai; Zhaoyang Song; Jing Sun; Yang Xiao; Danian Nie; Yu Zhang; Fen Huang; Hongsheng Zhou; Zhiping Fan; Sanfang Tu; Yonghua Li; Xutao Guo; Guopan Yu; Qifa Liu
Journal:  J Hematol Oncol       Date:  2013-02-08       Impact factor: 17.388
View more
  1 in total

1.  Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.

Authors:  Benigno C Valdez; Xiaowen Tang; Yang Li; David Murray; Yan Liu; Uday Popat; Richard E Champlin; Borje S Andersson
Journal:  Exp Hematol       Date:  2018-08-10       Impact factor: 3.084
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.